The data presented here show that co-administration of the oral ferroportin inhibitor VIT-2763 and the iron chelator DFX is feasible and might offer an opportunity to improve both erythropoiesis and iron overload in β-thalassemia. The gene discussed is SLC40A1; the disease is Tangier disease.